Cosela

Chemical Nametrilaciclib
Dosage FormInjection (intravenous; 300 mg)
Drug ClassKinase inhibitors
SystemRespiratory
CompanyG1 Therapeutics, Inc.
Approval Year2021

Indication

  • Indicated to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small cell lung cancer.
Last updated on 2/24/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Cosela (trilaciclib) Prescribing Information2021G1 Therapeutics, Inc. Durham, NC